证券代码：000952 证券简称：广济药业 公告编号：2025-042 湖北广济药业股份有限公司 关于 2021 年限制性股票激励计划部分限制性股票 回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： （二）2022 年 1 月 4 日，公司披露了《关于 2021 年限制性股票激励计划获得 湖北省国资委批复的公告》（公告编号：2022-001），公司收到湖北省人民政府国 有资产监督管理委员会《省政府国资委关于湖北广济药业股份有限公司实施限制性 股票激励计划的批复》（鄂国资考分〔2021〕69 号），原则同意广济药业实施限制 性股票激励计划。 1、本次回购注销限制性股票数量为 310.5 万股，约占回购注销前公司股本总 额的 0.89%。 2、本次回购注销限制性股票的回购金额合计 11,338,869.00 元，回购资金来 源为公司自有资金。 3、本次注销完成后，公司总股本由 349,855,339 股减少至 346,750,339 股。 4、截至本公告披露日，上述限制性股票已在中国证券登记结算有限责任公司 深圳分公司办理完成回购注销 ...

Group 1 - The Hong Kong stock market has seen nearly 80 billion yuan inflow through ETFs this year, with a strong preference for technology and internet sectors [1] - Personal pension fund scale has surpassed 12 billion yuan, with nearly 90% of products yielding positive returns since inception [1] - A new efficient and environmentally friendly lithium-ion battery recycling method has been developed, achieving over 92% recovery of key metals [2] Group 2 - A new RSV preventive drug, SIBP-A16, has received clinical trial approval, representing an upgrade in China's preventive antibody research system [3] - The Chinese Urban Public Transport Association issued an apology for misleading information regarding the ban on fuel vehicles in ride-hailing platforms [4] - Starbucks China has introduced "Starbucks Study Room" in some Guangdong stores to provide a study space for consumers [5] Group 3 - Coca-Cola announced the launch of a new cane sugar version of its product in the U.S. this fall as part of its innovation strategy [5] - Amazon is acquiring wearable device manufacturer Bee AI to enhance its AI capabilities [5] - Carlyle Group has hired a Goldman Sachs executive to expand its private credit business [5] Group 4 - China Rare Earth's executive director is involved in overdue debts exceeding 200 million yuan, with no reasonable explanation provided [6] - Guangji Pharmaceutical's vice president resigned following a penalty from the Hubei Securities Regulatory Commission, with expected losses of 67 to 83.5 million yuan for the first half of 2025 [7] - Guanglian Aviation's controlling shareholder is under investigation, but it is stated that this will not significantly impact normal operations [7] Group 5 - U.S. stock indices showed mixed results, with the Dow Jones rising by 0.4% while the Nasdaq fell by 0.39% [8] - General Motors' stock dropped over 8% due to performance decline influenced by tariffs, while Texas Instruments provided a pessimistic outlook for Q3 [9] - Bitcoin rose by 2.3%, while gold increased by over 1%, reaching a one-month high [9]

证券代码：000952 证券简称：广济药业 公告编号：2025-041 湖北广济药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 广济药业子公司湖北广济药业济康医药有限公司（以下简称济康医药）在与 部分客户开展经销业务时身份为代理人，应当采用净额法确认收入。对案涉经销 业务，济康医药采用总额法确认收入，导致广济药业 2022 年第一季度、半年度、 第三季度报告分别多计营业收入 4560.16 万元、13686.00 万元、13820.04 万元， 分别占当期营业收入的 25.49%、26.68%、20.49%。2023 年 4 月，广济药业发布 《关于前期会计差错更正的公告》，对 2022 年第一季度、半年度、第三季度报 告作出差错更正。 上述违法事实，有广济药业相关公告文件、相关核查报告、财务凭证、相关 人员询问笔录、情况说明等证据证明，足以认定。 广济药业上述行为涉嫌违反《证券法》第七十八条第二款、第八十四条第一 款的规定，构成《证券法》第一百九十七条第二款所述违法行为。 湖北广济药业股份有限公司于 2024 年 10 月 25 日收到中国 ...

证券代码：000952 证券简称：广济药业 公告编号：2025-041 湖北广济药业股份有限公司 关于收到《行政处罚决定书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 湖北广济药业股份有限公司于 2024 年 10 月 25 日收到中国证券监督管理委 员会（以下简称"中国证监会"）下发的《立案告知书》（编号：证监立案字 0052024009 号）。因公司涉嫌信息披露违法违规，根据《中华人民共和国证券 法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 具体内容详见公司于 2024 年 10 月 26 日在指定信息披露媒体上刊登的《关于收 到中国证券监督管理委员会〈立案告知书〉的公告》（公告编号：2024-064）。 当事人：湖北广济药业股份有限公司，住所：湖北省黄冈市武穴市。 阮澍，男，1975 年 6 月出生，住址：湖北省武汉市洪山区。 胡明峰，男，1970 年 3 月出生，住址：湖北省武汉市硚口区。 依据《中华人民共和国证券法》（以下简称《证券法》）的有关规定，我局 对湖北广济药业股份有限公司（以下简称广济药业）信息披露违法 ...

证券代码：000952 证券简称：广济药业 公告编号：2025-039 湖北广济药业股份有限公司 关于公司聘任董事会秘书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会秘书离任情况 湖北广济药业股份有限公司（以下简称"公司"）董事会秘书郑彬先生因工 作岗位调动原因，不再担任公司董事会秘书职务，但仍在公司任职。其岗位调动 不会影响董事会的正常运作及公司日常经营管理。 郑彬先生在担任公司董事会秘书期间，在公司治理、资本运作、信息披露、 投资者关系管理等方面勤勉敬业，恪尽职守。公司董事会对郑彬先生在其任职期 间所做的贡献表示衷心感谢！ 二、聘任董事会秘书情况 公司于 2025 年 7 月 21 日召开第十一届董事会第九次（临时）会议，审议通 过《关于聘任杨行虎先生为公司董事会秘书的议案》，经公司董事会提名委员会 资格审查通过，建议聘任杨行虎先生为公司董事会秘书（个人简历附后），任期 自本次董事会通过之日起至第十一届董事会届满日止。 杨行虎先生具备履行董事会秘书职责所必需的财务、管理、法律专业知识， 具有良好的职业道德和个人品德，并于 2025 年 ...

湖北广济药业股份有限公司 关于公司副总经理辞职的公告 证券代码：000952 证券简称：广济药业 公告编号：2025-040 特此公告。 湖北广济药业股份有限公司董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2025 年 7 月 21 日 湖北广济药业股份有限公司（以下简称"公司"）董事会于近日收到副总经 理胡明峰先生递交的书面辞职报告，因工作岗位调动原因，胡明峰先生申请辞去 公司副总经理职务。辞任后，胡明峰先生仍在公司任职。 根据《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳证 券交易所上市公司自律监管指引第 1 号－－主板上市公司规范运作》和《公司章 程》的有关规定，胡明峰先生的辞职报告自送达公司董事会之日起生效，其辞职 不会对公司的正常运营产生影响。 胡明峰先生原定任期至公司第十一届董事会届满之日止。截至本公告披露之 日，胡明峰先生持有公司 2021 年限制性股票激励计划已获授但尚未解除限售的 限制性股票 66,000 股，其股份变动将严格遵循《公司 2021 年限制性股票激励计 划》《公司 2021 年限制性股票激励计划实施考核 ...

2、会议的时间和方式：2025 年 7 月 21 日上午 10 点在湖北广济药业股份有 限公司（以下简称"公司"）武穴市大金产业园行政楼二楼会议室以现场结合通 讯的方式召开； 3、本次会议应到董事 9 人（含独立董事 3 人），实到董事 9 人，龚铖先生、 郭韶智先生为现场表决，胡立刚先生、方智先生、刘波先生、石守东先生、郭炜 先生、洪葵女士、梅建明先生为通讯表决； 证券代码：000952 证券简称：广济药业 公告编号：2025-038 湖北广济药业股份有限公司 第十一届董事会第九次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 1、会议通知的时间和方式：会议通知于 2025 年 7 月 14 日以专人送达、书 面传真和电子邮件形式发出； 4、本次会议由董事长胡立刚先生主持，全体监事列席本次会议； 5、本次会议的召开符合《中华人民共和国公司法》和《公司章程》的有关 规定，会议决议合法、有效。 二、董事会会议审议情况 审议通过《关于聘任杨行虎先生为公司董事会秘书的议案》 经董事会提名委员会资格审查，同意聘任杨行虎先生 ...

Summary of Key Points Core Viewpoint - The company, Hubei Guangji Pharmaceutical Co., Ltd., has announced an expected net profit loss for the first half of 2025, indicating challenges in financial performance despite some operational improvements [1]. Financial Performance - The performance forecast period is from January 1, 2025, to June 30, 2025, with an anticipated net profit being negative [1]. - The company has communicated with its accounting firm regarding the performance forecast, and there are no discrepancies noted [1]. Reasons for Performance Changes - The increase in net profit attributable to shareholders compared to the same period last year is primarily due to: 1. Implementation of a "streamlined and efficient" management approach, reducing management levels and internal departments, which has improved management efficiency and lowered costs [1]. 2. The Jining company has reduced production in response to market conditions, leading to a decrease in unnecessary personnel and a reduction in losses compared to the previous year [1]. 3. Strengthened market cooperation and enhanced customer communication have resulted in increased sales for certain product specifications in both raw materials and formulations compared to the previous year [1].

[Hubei Guangji Pharmaceutical Co., Ltd. 2025 Interim Results Forecast](index=1&type=section&id=%E6%B9%96%E5%8C%97%E5%B9%BF%E6%B5%8E%E8%8D%AF%E4%B8%9A%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B82025%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A) The company forecasts a continued net loss for H1 2025, but with a significant year-over-year reduction [Performance Forecast for the Current Period](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company anticipates a net loss attributable to shareholders for H1 2025, but with a notable reduction compared to the prior year H1 2025 Performance Forecast | Item | Current Reporting Period | Same Period Last Year | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | **Loss: RMB 67.00 million - 83.50 million** | Loss: RMB 106.65 million | | YoY Change | Loss Reduction: 21.70% - 37.17% | - | | **Net Profit after Non-recurring Items** | **Loss: RMB 70.00 million - 86.50 million** | Loss: RMB 115.67 million | | YoY Change | Loss Reduction: 25.22% - 39.48% | - | | **Basic Earnings Per Share** | **Loss: RMB 0.1915/share - 0.2387/share** | Loss: RMB 0.3014/share | [Communication with the Accounting Firm](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5) The company has communicated with its accounting firm regarding the forecast, with no disagreements on the content - The company has pre-communicated with its accounting firm regarding the performance forecast, and **no disagreements exist** between the two parties[4](index=4&type=chunk) - This performance forecast **has not been audited** by a certified public accountant[4](index=4&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The year-over-year improvement in net profit is attributed to cost reduction, subsidiary adjustments, and sales growth [Management Optimization and Cost Control](index=1&type=section&id=3.1%20%E7%AE%A1%E7%90%86%E4%BC%98%E5%8C%96%E4%B8%8E%E6%88%90%E6%9C%AC%E6%8E%A7%E5%88%B6) The company enhanced management efficiency and lowered costs by streamlining its organizational structure - During the reporting period, the company restructured its management organization based on the principle of **'streamlined and efficient'** to improve management effectiveness and reduce administrative costs[5](index=5&type=chunk) [Subsidiary Operational Adjustments](index=1&type=section&id=3.2%20%E5%AD%90%E5%85%AC%E5%8F%B8%E7%BB%8F%E8%90%A5%E8%B0%83%E6%95%B4) The Jining subsidiary reduced its losses year-over-year by scaling back production and personnel due to unfavorable market prices - The Jining subsidiary **reduced its losses year-over-year** by systematically scaling back production and non-essential personnel in response to lower-than-expected market prices[5](index=5&type=chunk) [Market and Sales Expansion](index=1&type=section&id=3.3%20%E5%B8%82%E5%9C%BA%E4%B8%8E%E9%94%80%E5%94%AE%E6%8B%93%E5%B1%95) The company achieved sales growth for certain products by strengthening market cooperation and expanding sales channels - The company achieved **year-over-year sales growth** for certain specifications of its raw material and formulation series products by strengthening market partnerships and expanding sales channels[5](index=5&type=chunk) [Risk Warning](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The performance forecast is a preliminary estimate, and final data will be in the official interim report - This performance forecast is a preliminary result from the company's finance department; specific financial data will be based on the **official 2025 interim report**[6](index=6&type=chunk) - Investors are advised to **make prudent decisions** and be aware of investment risks[6](index=6&type=chunk)

Core Viewpoint - Guangji Pharmaceutical (000952) has received approval from the National Health Commission for its application of 2'-fucosyllactose, a significant step towards the product's industrialization [1] Group 1: Product Approval - The application for 2'-fucosyllactose has passed the administrative review and has been officially announced [1] - 2'-fucosyllactose is a oligosaccharide abundant in breast milk, known for its benefits in regulating gut microbiota, promoting brain development, and enhancing immunity [1] - The product is included in the list of food nutrition fortifiers, allowing its use in infant formula and milk powder [1] Group 2: Research and Development - The successful approval of 2'-fucosyllactose is a result of the company's independent research and development efforts [1] - The approval meets national technical review standards, laying a solid foundation for the company's advancement in product industrialization [1]